Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
InvestmentPitch Media Video Discusses Love Pharma, a New Listing on the CSE, Focused on the Global Sexual Health, Wellness, and Psychedelics Markets - Video Available on Investmentpitch.com
InvestmentPitch Media Video Discusses Tocvan's Acquisition of 100% Interest in Rogers Creek Copper Porphyry Property in SW British Columbia and Announces Spin-Out Transaction - Video News Alert on Investmentpitch.com